PIKTOR Plus Paclitaxel Yields Responses in Pretreated PAM-Mutated Endometrial Cancer

Faeth Reports Positive Preliminary Phase 2 Topline Results from the PIK-201 Trial Evaluating PIKTOR in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Nov 9, 2026-

Faeth reports 33% response rate in trial of PIKTOR in EEC - BioTuesdays

Faeth Therapeutics (NASDAQ: FTH) has reported preliminary Phase 2 clinical results showing a confirmed objective response rate of 33% for its investigational PIKTOR treatment combined with paclitaxel in patients with advanced endometrioid endometrial cancer (EEC). Faeth has also reported a disease control rate of 83% and preliminary median progression-free survival of 7.4 months in its […]

PIKTOR Plus Paclitaxel Yields Responses in Pretreated PAM-Mutated Endometrial Cancer

Results showed a 33% confirmed ORR and a 7.4-month median PFS with serabelisib and sapanisertib plus paclitaxel in advanced endometrioid endometrial cancer.